RELMADA THERAPEUTICS, INC. current report, 02 February 2018

Full document

RELMADA THERAPEUTICS, INC. - 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the 2017 Annual Meeting of Stockholders held by Relmada Therapeutics, Inc. on February 2, 2018. The filing details the voting results for director elections, auditor ratification, equity plan amendments, and executive compensation.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.

Material Changes and Voting Results

Of the 12,057,858 shares eligible to vote, 6,350,557 shares (approximately 52.7%) were present in person or by proxy. All four proposals submitted were approved:

  • Proposal 1 (Director Election): Paul Kelly was elected as a Class III director for a 36-month term. Votes: 5,823,660 For, 526,212 Against, 685 Abstain.
  • Proposal 2 (Auditor Ratification): GBH CPAs, PC was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2018. Votes: 5,823,660 For, 526,212 Against, 685 Abstain.
  • Proposal 3 (Equity Plan Amendment): An amendment to increase the authorized shares under the 2014 Stock Option and Equity Incentive Plan by 2.5 million shares was approved. Votes: 3,120,503 For, 1,391,038 Against, 25,511 Abstain.
  • Proposal 4 (Executive Compensation): A non-binding vote on 2017 executive compensation was approved. Votes: 4,250,455 For, 248,565 Against, 38,032 Abstain.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the Annual Meeting results.

Key Facts for Investor Verification

  • Paul Kelly's election as a Class III director for a three-year term.
  • The successful ratification of GBH CPAs, PC as the independent auditor.
  • The approval to increase the equity incentive plan pool by 2.5 million shares.
  • The significant number of broker non-votes (1,813,505) recorded for Proposals 1, 3, and 4.